therapy with miRNA to improve the prognosis of patients with this pathology. © 2022 The Authors
Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа, a promising direction is NF1
therapy with STAT3 inhibitors and immune checkpoint inhibitors